SOHO 2024: Focus on CLL
Liso-cel monotherapy was found to be effective even in patients with high-risk disease features.
The study's results illustrate the effects of these abnormalities and the importance of screening.
Over a three-year study period ibrutinib use in the US decreased while acalabrutinib and zanubrutinib use increased.
Dr. Rogers debated against Inhye Ahn, MD, on whether therapy with Bruton tyrosine kinase inhibitors can be discontinued.
The past year in CLL care has seen promising new study findings on BTK inhibition and regulatory approvals.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.